tradingkey.logo
๎™

Titan Pharmaceuticals Inc

TTNP
๎˜น
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

4.310USD

+0.130+3.11%
์ข…๊ฐ€ย 09/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
5.73M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Titan Pharmaceuticals Inc

4.310

+0.130+3.11%
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

+3.11%

5์ผ

+0.47%

1๊ฐœ์›”

-15.49%

6๊ฐœ์›”

+17.76%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+32.21%

1๋…„

-22.48%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

TradingKey ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-09-19

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

ํšŒ์‚ฌ์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•„์ฃผ ๊ฑด์ „ํ•œํ•œ ํŽธ์ž…๋‹ˆ๋‹ค. ํšŒ์‚ฌ์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ์œผ๋กœ ๊ฐ„์ฃผ๋ฉ๋‹ˆ๋‹ค. ๊ธฐ๊ด€์˜ ์ธ์ง€๋„๋Š” ๋งค์šฐ ๋†’์€์ž…๋‹ˆ๋‹ค. ์ฃผ์‹์‹œ์žฅ์—์„œ ๊ฐ•ํ•œ ์„ฑ๊ณผ์™€ ์šฐ์ˆ˜ํ•œ ํŽ€๋”๋ฉ˜ํ„ธ์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ , ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋Š” ํ˜„์žฌ์˜ ์ถ”์„ธ๋ฅผ ๋’ท๋ฐ›์นจํ•˜์ง€ ๋ชปํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
249 / 506
์ „์ฒด ์ˆœ์œ„
407 / 4720
์‚ฐ์—…
์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๋ฐ์ดํ„ฐ ์—†์Œ

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

0 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
--
ํ˜„์žฌ ๋“ฑ๊ธ‰
--
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
--
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

๊ธฐ์—… ํ•˜์ด๋ผ์ดํŠธ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
๊ณผ์†Œ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -1.47๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋‚ฎ์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 414.53K์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 9.21% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
์ œ์ž„์Šค ์‚ฌ์ด๋จผ์Šค๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž ์ œ์ž„์Šค ์‚ฌ์ด๋จผ์Šค์ด(๊ฐ€) ์ด ์ฃผ์‹ 11.38K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ์ฆ๊ฐ€
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ ธ, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด -0.49์ž…๋‹ˆ๋‹ค.

๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๋ฐ์ดํ„ฐ ์—†์Œ

์ด ์ˆ˜์ต

๋ฐ์ดํ„ฐ ์—†์Œ

ํšŒ์‚ฌ๎˜

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
์ข…๋ชฉ ์ฝ”๋“œ TTNP
ํšŒ์‚ฌTitan Pharmaceuticals Inc
CEOMr. Weei Jye Chay
์›น์‚ฌ์ดํŠธhttps://www.titanpharm.com/
tradingkey.logo
๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ์ด์šฉ ์•ฝ๊ด€์ด ์ ์šฉ๋ฉ๋‹ˆ๋‹ค. ์—ญ์‚ฌ์  ๋ฐ ํ˜„์žฌ ์ข…๊ฐ€ ๋ฐ์ดํ„ฐ๋Š” Refinitiv์—์„œ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ชจ๋“  ์‹œ์„ธ๋Š” ํ˜„์ง€ ๊ฑฐ๋ž˜์†Œ ์‹œ๊ฐ„ ๊ธฐ์ค€์ž…๋‹ˆ๋‹ค. ๋ฏธ๊ตญ ์ฃผ์‹ ์‹œ์„ธ์˜ ์‹ค์‹œ๊ฐ„ ๋งˆ์ง€๋ง‰ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” Nasdaq์„ ํ†ตํ•ด ๋ณด๊ณ ๋œ ๊ฑฐ๋ž˜๋งŒ ๋ฐ˜์˜๋ฉ๋‹ˆ๋‹ค. ๋‹น์ผ ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ๋Š” ์ตœ์†Œ 15๋ถ„ ์ง€์—ฐ๋˜๊ฑฐ๋‚˜ ๊ฑฐ๋ž˜์†Œ ์š”๊ตฌ ์‚ฌํ•ญ์— ๋”ฐ๋ผ ๋‹ค๋ฅผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
* ์ฐธ๊ณ ์ž๋ฃŒ, ๋ถ„์„ ๋ฐ ํŠธ๋ ˆ์ด๋”ฉ ์ „๋žต์€ ์ œ3์ž ์ œ๊ณต์—…์ฒด์ธ Trading Central์—์„œ ์ œ๊ณตํ•˜๋ฉฐ, ๋ถ„์„๊ฐ€์˜ ๋…๋ฆฝ์ ์ธ ํ‰๊ฐ€์™€ ํŒ๋‹จ์— ๊ธฐ๋ฐ˜ํ•œ ์‹œ๊ฐ์œผ๋กœ, ํˆฌ์ž์ž์˜ ํˆฌ์ž ๋ชฉํ‘œ์™€ ์žฌ์ • ์ƒํ™ฉ์€ ๊ณ ๋ ค๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ 
KeyAI
๎™